State Of Wyoming Bei Gene, Ltd. Transaction History

State Of Wyoming

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $28,945 - $51,635	239 Added 31.7%	993 $161,000
Q1 2022 May 13, 2022	BUY	$146.52 - $269.56 $18,608 - $34,234	127 Added 20.26%	754 $142,000
Q4 2021 Feb 11, 2022	SELL	$248.56 - $389.34 $8,451 - $13,237	-34 Reduced 5.14%	627 $170,000
Q3 2021 Feb 11, 2022	SELL	$249.6 - $403.14 $79,372 - $128,198	-318 Reduced 32.48%	661 $240,000
Q2 2021 Feb 11, 2022	BUY	$292.75 - $367.01 $151,644 - $190,111	518 Added 112.36%	979 $336,000
Q1 2021 Feb 08, 2022	BUY	$260.64 - $382.12 $120,155 - $176,157	461 New	461 $160,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.